Notice of Correction: Results of ACOSOG Z0050 trial: The utility of FDG-PET in staging potentially operable non–small cell lung cancer

Article Outline

• References
• Copyright

To the Editor:

As the result of re-review of data from the American College of Surgeons Oncology Group Z0050 trial¹ in preparation for an analysis of the use of brain FDG-PET in operable lung cancer,² some corrections to the originally published data are reported. As published, FDG-PET correctly identified M1 disease in 15 of 287 patients (5.2%). It was reported that in 19 of 287 evaluable patients (6.6%) possible M1 disease was ruled out with confirmatory procedures (additional imaging or biopsy). Re-review of the PET reports in this group revealed that two cases (1 brain, 1 bone) were erroneously included by only blinded PET review and 4 cases (3 brain, 1 esophagus) were not suspicious per site PET report re-read. It was also reported that M1 disease was indicated by PET in 8 additional patients that the surgeon chose to overrule. Re-review shows that two cases (1 brain, 1 esophagus) were erroneously included.

These corrections do not alter the conclusions of the ACOSOG Z0050 trial. However, the reported percentage of patients with PET findings indicative of M1 disease subsequently proven not to be metastatic decreases from 6.6% to 4.5%.

Back to Article Outline

References 

1. Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BR, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: The utility of positron emission tomography in staging potentially operable non–small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:1943–1951
   • View In Article
   • Abstract
   • Full Text
   • Full-Text PDF (115 KB)
   • CrossRef
2. Posther KE, McCall LM, Harpole DH, Reed CE, Rusch VW, Siegel BA. Yield of brain FDG-PET in evaluating patients with potentially operable non–small cell lung cancer. J Nuc Med. 2006;47:1607–1611
   • View In Article